Nantkwest (NK) Price Target Lowered to $3.00 at Citigroup

Nantkwest (NASDAQ:NK) had its price target reduced by Citigroup to $3.00 in a research note released on Sunday.

Other equities research analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Nantkwest from a hold rating to a buy rating and set a $4.25 target price on the stock in a research report on Wednesday, October 10th. ValuEngine upgraded shares of Nantkwest from a hold rating to a buy rating in a research report on Thursday, November 1st. BidaskClub upgraded shares of Nantkwest from a sell rating to a hold rating in a research report on Friday, September 28th. Finally, Jefferies Financial Group reiterated a hold rating and set a $3.50 target price on shares of Nantkwest in a research report on Thursday, November 15th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of Hold and a consensus price target of $3.58.

Shares of Nantkwest stock opened at $1.67 on Friday. The company has a market cap of $135.48 million, a P/E ratio of -1.39 and a beta of 3.09. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.31 and a current ratio of 3.31. Nantkwest has a 1 year low of $1.62 and a 1 year high of $5.47.

In related news, Director Steve Gorlin sold 100,000 shares of Nantkwest stock in a transaction that occurred on Tuesday, November 27th. The shares were sold at an average price of $1.75, for a total transaction of $175,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 469,251 shares of company stock worth $919,880. 72.30% of the stock is owned by corporate insiders.

Large investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP lifted its position in shares of Nantkwest by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 241,815 shares of the biotechnology company’s stock worth $895,000 after purchasing an additional 25,543 shares during the period. Millennium Management LLC lifted its position in shares of Nantkwest by 27.9% in the 2nd quarter. Millennium Management LLC now owns 200,430 shares of the biotechnology company’s stock worth $613,000 after purchasing an additional 43,686 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Nantkwest by 40.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 170,271 shares of the biotechnology company’s stock worth $521,000 after purchasing an additional 49,040 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Nantkwest by 132.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 111,641 shares of the biotechnology company’s stock worth $413,000 after purchasing an additional 63,689 shares during the period. Finally, Bridgeway Capital Management Inc. lifted its position in shares of Nantkwest by 75.0% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 175,000 shares of the biotechnology company’s stock worth $648,000 after purchasing an additional 75,000 shares during the period. Institutional investors and hedge funds own 13.55% of the company’s stock.

Nantkwest Company Profile

NantKwest, Inc, a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Further Reading: Why does a company issue an IPO?

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply